Clinical and Genomic Epidemiology of Carbapenem-Nonsusceptible Citrobacter spp. at a Tertiary Health Care Center over 2 Decades-Reference-Cited by-同舟云学术

Clinical and Genomic Epidemiology of Carbapenem-Nonsusceptible Citrobacter spp. at a Tertiary Health Care Center over 2 Decades

Published:2020-08-24 Issue:9 Volume:58 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Babiker Ahmed¹²^ORCID,Evans Daniel R.¹,Griffith Marissa P.¹²,McElheny Christi L.¹,Hassan Mohamed³,Clarke Lloyd G.¹,Mettus Roberta T.¹,Harrison Lee H.¹²⁴,Doi Yohei¹,Shields Ryan K.¹,Van Tyne Daria¹^ORCID

Affiliation:

1. Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

2. Microbial Genomic Epidemiology Laboratory, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

3. Division of General Internal Medicine, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

4. Graduate School of Public Health, University of Pittsburgh, Pennsylvania, USA

Abstract

Carbapenem-nonsusceptible Citrobacter spp. (CNSC) are increasingly recognized as health care-associated pathogens. Information regarding their clinical epidemiology, genetic diversity, and mechanisms of carbapenem resistance is lacking. We examined microbiology records of adult patients at the University of Pittsburgh Medical Center (UMPC) Presbyterian Hospital (PUH) from 2000 to 2018 for CNSC, as defined by ertapenem nonsusceptibility. Over this time frame, the proportion of CNSC increased from 4% to 10% ( P = 0.

Funder

University of Pittsburgh Department of Medicine

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.00275-20

Reference51 articles.

1. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

2. External Validation of Difficult-to-Treat Resistance Prevalence and Mortality Risk in Gram-Negative Bloodstream Infection Using Electronic Health Record Data From 140 US Hospitals

3. Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States

4. WHO. 2017. Global priority list of antibiotic-resistant bacteria to guide research, discover, and development of new antibiotics. World Health Organization, Geneva, Switzerland.

5. CDC. 2019. Antibiotic resistance threats in the United States. U.S. Department of Health and Human Services, CDC, Atlanta, GA.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emergence and plasmid cointegration-based evolution of NDM-1-producing ST107 Citrobacter freundii high-risk resistant clone in China;International Journal of Antimicrobial Agents;2024-02

2. A brief insight into Citrobacter species - a growing threat to public health;Frontiers in Antibiotics;2023-12-05

3. Comparison of carbapenem-susceptible and carbapenem-resistant Enterobacterales at nine sites in the USA, 2013–2016: a resource for antimicrobial resistance investigators;Microbial Genomics;2023-11-21

4. Carbapenem-resistant Citrobacter freundii harboring blaKPC−2 and blaNDM−1: a study on their transferability and potential dissemination via generating a transferrable hybrid plasmid mediated by IS6100;Frontiers in Microbiology;2023-08-17

5. Genomic dissection of endemic carbapenem resistance reveals metallo-beta-lactamase dissemination through clonal, plasmid and integron transfer;Nature Communications;2023-08-08